-$0.06 EPS Expected for VBI Vaccines Inc (NASDAQ:VBIV) This Quarter

Share on StockTwits

Wall Street brokerages expect VBI Vaccines Inc (NASDAQ:VBIV) to report earnings per share of ($0.06) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.07) to ($0.05). VBI Vaccines reported earnings per share of ($0.28) in the same quarter last year, which would indicate a positive year over year growth rate of 78.6%. The business is expected to issue its next quarterly earnings report on Monday, February 24th.

According to Zacks, analysts expect that VBI Vaccines will report full-year earnings of ($0.47) per share for the current year, with EPS estimates ranging from ($0.48) to ($0.45). For the next financial year, analysts anticipate that the company will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.21) to ($0.15). Zacks’ EPS calculations are an average based on a survey of research analysts that follow VBI Vaccines.

VBI Vaccines (NASDAQ:VBIV) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). VBI Vaccines had a negative return on equity of 70.54% and a negative net margin of 1,458.97%. The business had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.90 million.

Several research firms have commented on VBIV. Raymond James began coverage on shares of VBI Vaccines in a report on Thursday, November 14th. They issued an “outperform” rating and a $3.00 target price on the stock. Zacks Investment Research lowered shares of VBI Vaccines from a “buy” rating to a “hold” rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $3.81.

VBIV stock traded down $0.04 during mid-day trading on Wednesday, hitting $0.82. The stock had a trading volume of 3,461,023 shares, compared to its average volume of 1,686,317. The company has a current ratio of 1.88, a quick ratio of 1.84 and a debt-to-equity ratio of 0.01. VBI Vaccines has a 52 week low of $0.47 and a 52 week high of $2.20. The firm has a market capitalization of $160.13 million, a P/E ratio of -0.85 and a beta of 0.79. The firm has a fifty day simple moving average of $0.63 and a 200 day simple moving average of $0.88.

In related news, major shareholder Perceptive Advisors Llc purchased 20,000,000 shares of the firm’s stock in a transaction that occurred on Monday, September 23rd. The shares were bought at an average cost of $0.50 per share, with a total value of $10,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jeff Baxter purchased 150,000 shares of the firm’s stock in a transaction that occurred on Monday, September 30th. The shares were bought at an average cost of $0.50 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 608,255 shares in the company, valued at approximately $304,127.50. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 30,212,000 shares of company stock worth $15,105,440. Insiders own 10.50% of the company’s stock.

Several institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can grew its holdings in shares of VBI Vaccines by 71.8% during the 2nd quarter. Bank of Montreal Can now owns 37,604 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 15,717 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of VBI Vaccines during the 2nd quarter valued at approximately $25,000. Citadel Advisors LLC bought a new stake in shares of VBI Vaccines during the 2nd quarter valued at approximately $31,000. Susquehanna International Group LLP bought a new stake in shares of VBI Vaccines during the 2nd quarter valued at approximately $58,000. Finally, Weil Company Inc. grew its holdings in shares of VBI Vaccines by 228.6% during the 2nd quarter. Weil Company Inc. now owns 71,875 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 50,000 shares during the last quarter. 40.91% of the stock is currently owned by institutional investors.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.

Further Reading: What is the Russell 2000 Index?

Get a free copy of the Zacks research report on VBI Vaccines (VBIV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
iShares Agency Bond ETF  Shares Bought by Clean Yield Group
iShares Agency Bond ETF Shares Bought by Clean Yield Group
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated


 
© 2006-2020 Zolmax.